News Peg. The FDA granted Lilly a fast-track designation for weight loss in October 2022, just months after it was authorized for use in type 2 diabetics. It is one of several diabetes drugs to ...

New weight loss drug on fast-track to rival Ozempic, Wegovy Drugmaker Eli Lilly said it's seeking FDA approval of its drug Mounjaro to treat weight loss after late-stage trials showed ...

Mounjaro works in several ways to control blood sugar and also help with weight loss: To maintain the effects of Mounjaro, you need to keep taking the medicine. In a study to see if tirzepatide helps ...

The latest study findings were based on outcomes from patients prescribed either Ozempic or Mounjaro, because at the time of the study, tirzepatide had not yet been approved for weight loss.

Mounjaro has gained popularity for treating type 2 diabetes and aiding weight loss. But it may not be suitable for everyone. Some people can’t get a prescription or afford the high cost.

The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit of new treatments for obesity. ... More than 170 drugs are now in the tracker.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Ozempic and Mounjaro increase weight loss. ... that cult drugs like Ozempic and Mounjaro are being touted as the ultimate ...

People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. CNN values your feedback 1.

(CNN) -- People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.